Artivion, Inc.
$38.8
▲
0.03%
2026-04-21 05:19:01
artivion.com
NYQ: AORT
Explore Artivion, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.89 B
Current Price
$38.8
52W High / Low
$48.25 / $22.22
Stock P/E
193.48
Book Value
$9.37
Dividend Yield
—
ROCE
3.41%
ROE
2.7%
Face Value
—
EPS
$0.21
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
1,800
Beta
1.62
Debt / Equity
57.67
Current Ratio
3.53
Quick Ratio
2.62
Forward P/E
32.55
Price / Sales
4.14
Enterprise Value
$2 B
EV / EBITDA
37.09
EV / Revenue
4.52
Rating
Buy
Target Price
$51.43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Treace Medical Concepts, Inc. | $1.97 | — | $125.31 M | — | -33.86% | -58.94% | $7.78 / $1.17 | $1.37 |
| 2. | Accuray Incorporated | $0.46 | — | $52.79 M | — | 2.82% | -70.32% | $2.1 / $0.33 | $0.45 |
| 3. | LivaNova PLC | $65.81 | — | $3.6 B | — | 11.09% | -19.24% | $71.92 / $34 | $21.96 |
| 4. | TransMedics Group, Inc. | $113.13 | 20.39 | $3.88 B | — | 11.09% | 54.24% | $156 / $84.53 | $13.81 |
| 5. | Perspective Therapeutics, Inc. | $4.55 | — | $478.52 M | — | -47.66% | -41.65% | $6.16 / $1.75 | $2.79 |
| 6. | Rapid Micro Biosystems, Inc. | $2.25 | — | $103.66 M | — | -84.08% | -86.82% | $4.94 / $2.01 | $0.75 |
| 7. | electroCore, Inc. | $6.31 | — | $51.01 M | — | -179.71% | -4.79% | $8.64 / $4.16 | $-0.21 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 115.99 M | 113.39 M | 112.97 M | 98.98 M | 97.31 M | — |
| Operating Profit | 7.18 M | 9.04 M | 8.38 M | 2.15 M | 2.67 M | — |
| Net Profit | 2.43 M | 6.5 M | 1.34 M | -0.51 M | -16.48 M | — |
| EPS in Rs | 0.05 | 0.13 | 0.03 | -0.01 | -0.34 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 441.33 M | 388.54 M | 354 M | 313.79 M |
| Operating Profit | 26.75 M | 38.87 M | -8.51 M | 6.2 M |
| Net Profit | 9.77 M | -13.36 M | -30.69 M | -19.19 M |
| EPS in Rs | 0.2 | -0.28 | -0.63 | -0.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 884.8 M | 789.1 M | 792.4 M | 762.8 M |
| Total Liabilities | 436.56 M | 512.9 M | 510.62 M | 478.47 M |
| Equity | 448.23 M | 276.2 M | 281.78 M | 284.33 M |
| Current Assets | 358.08 M | 290.08 M | 280.67 M | 247.33 M |
| Current Liabilities | 101.56 M | 66.82 M | 57.86 M | 49.67 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 39.88 M | 22.24 M | 18.82 M | -5.15 M |
| Investing CF | -42.04 M | -28.19 M | -0.5 M | -10.71 M |
| Financing CF | 11.28 M | 2.2 M | 0.86 M | -1.64 M |
| Free CF | 0.84 M | 11.05 M | 9.07 M | -15.87 M |
| Capex | -39.04 M | -11.19 M | -9.75 M | -10.71 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.75% | 12.82% | — | — |
| Earnings Growth % | 56.47% | -59.91% | — | — |
| Profit Margin % | -3.44% | -8.67% | -6.12% | — |
| Operating Margin % | 10.01% | -2.4% | 1.98% | — |
| Gross Margin % | 64.03% | 64.74% | 64.54% | — |
| EBITDA Margin % | 13.12% | 7.57% | 8.18% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.